An observational study in Cardiac Amyloidosis, sponsored by Saving Lives Matters. Recruiting at 1 site in France. Per ClinicalTrials.gov, last updated 2021-11-01.
Sponsored by Saving Lives Matters · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Amyloid Neuropathies, Familial with a site in France — 15 open to participants now, 16 under way, 1 of them phase 3. Amyloid Neuropathies, Familial · France.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, this one is the 2nd largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2021, is one of 12 observational ones, reaches primary completion later than 7 of the 15 other live ones, and was the 25th registered.
188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.
Browse Amyloid Neuropathies, Familial studies →15 of the 35 studies in Amyloid Neuropathies, Familial with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Ages 18+
Centre Hospitalier Universitaire Dijon · Sites in France
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in France, United States, Argentina and 21 more countries
Ages 18–75
Gérond'if · Sites in France
Ages 80+
University Hospital, Strasbourg, France · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10
First in 2007; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 233 across 92 observational studies indexed under Amyloid Neuropathies, Familial.
Median enrollment 128 across the 23 interventional studies, 175 across the 12 observational. Of the 19 that completed or were terminated, 10 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 35 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Saving Lives Matters as lead sponsor.
Saving Lives Matters has 1 study filed under Amyloid Neuropathies, Familial — fewer than ten, so there is no comparison to draw.
5 of the studies in Amyloid Neuropathies, Familial with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05103943Centre Hospitalier Régional d'OrléansAmyloidosis TTR Flow Reserve Evaluation | 2026-12-11 |
| NCT04849754GCS Ramsay Santé pour l'Enseignement et la RechercheAnalysis of the Evolution of SUVmax by Quantitative Analysis Method of Bisphosphonate Scintigraphy | 2026-12-31 |
| NCT04535349University Hospital, CaenQuantitative Analysis of Myocardial Uptake of Bone Radiopharmaceuticals in Patients With Cardiac ATTR Amyloidosis | 2027-06-15 |
| NCT05101304Saving Lives MattersRegistre HEAR, Healthcare European Amyloidosis Registry | 2027-06-30 |
| NCT06427304Gérond'ifCardiac Amyloidosis pRevaleNce of in OLDer Subjects Affected by Heart Failure | 2027-07-02 |
Add all 5 to your calendar (.ics) → With an account.
Among the 35 studies in Amyloid Neuropathies, Familial with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a non-interventional, prospective, retrospective, non-comparative, multi-center study.
In order not to interfere with patient management, the study is observational. Thus, no follow-up visit is imposed. The data collection will be limited to the data related to the management of the patients included throughout their follow-up.
This study is intended for all patients with a confirmed or suspected diagnosis of cardiac amyloidosis. Three cohorts will be identified: the HEAR (Healthcare European Amyloidosis Registry)-Retrospective Cohort, the HEAR(Healthcare European Amyloidosis Registry)-Retrospective-Prospective Cohort and the HEAR (Healthcare European Amyloidosis Registry)-Prospective Cohort.
Amyloidosis is a rare disease characterized by infiltration and continuous accumulation of insoluble fibrillar proteins in the extracellular matrix in various organs including kidney, nerve, liver, heart and skeletal muscle. Its prevalence is estimated at 0.5-1.3/100,000. The main forms are:
There is a strong need to help physicians better characterize the clinical and biological presentations of the disease and to improve diagnostic tools and standardize therapeutic management.
All data collected for the study are key, routine data for the condition, readily available in the patients' medical records. It is also possible to use additional and specific computerized tools to collect these data, within the participating expert centers.
Data will be recorded in an electronic observation book.
This study is intended for all patients with a confirmed or suspected diagnosis of cardiac amyloidosis.
INCLUSION CRITERIA
Patients must meet all of the following inclusion criteria to be included in the study:
Prospective Cohort:
Patients referred or who have been referred to the participating centre for suspected amyloidosis.
Patient who signed the patient information "Prospective Cohort" note
Retro-prospective Cohort:
Patient already followed in the center with a confirmed diagnosis of amyloidosis Patient who signed the "retro-prospective cohort" patient information note
Deceased patients followed in the center with a confirmed diagnosis of amyloidosis
Study participants will not be compensated for their participation
EXCLUSION CRITERIA The patient has expressed his/her refusal to participate Participation in another study, even an interventional one, is not a criterion for non-inclusion.
Retrospective collection of deceased patients data with inclusion criteria
Retrospective and prospective collection of patient data and real-life follow-up of patients from the date of inclusion Living patients who met the inclusion criteria
Prospective data collection and real-life follow-up of patients from the date of inclusion These patients are either newly followed in the centre with the inclusion criteria
The clinical, biological and imaging characteristics of patients with cardiac amyloidosis
Describe the clinical, biological and imaging characteristics of patients with cardiac amyloidosis.
Time frame: 6 years
he prevalence and incidence of the different types of amyloidosis and their evolution.
To estimate the prevalence and incidence of the different types of amyloidosis and their evolution.
Time frame: 6 years
The therapeutic management (cardiological and specific), their beneficial and secondary effects.
Describe the therapeutic management (cardiological and specific), their beneficial and secondary effects.
Time frame: 6 years
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2021 (actual). Primary completion is estimated for Jun 2027, 72 months after the start.
Of 74 observational studies under Amyloid Neuropathies, Familial, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 120. This study's planned 72 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyloid Neuropathies, Familial →